Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 309-323 , June 2009

Vasculitis in children

  • Despina Eleftheriou, MBBS, MRCPCH (Clinical Research Fellow in Vasculitis)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 20 79052392; Fax: +44 2078138494.
    • ,
  • Paul A. Brogan, BSc (Hon), MBChB (Hon), MRCP, MRCPCH, MSc, PhD (Senior Lecturer and Consultant in Paediatric Vasculitis)

References 

  1. Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep. 2000;2:411–416
  2. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–941
  3. Saulsbury FT. Clinical update: Henoch-Schonlein purpura. Lancet. 2007;369:976–978
  4. Gedalia A. Henoch-Schonlein purpura. Curr Rheumatol Rep. 2004;6:195–202
  5. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197–1202
  6. Yang YH, Chuang YH, Wang LC, et al. The immunobiology of Henoch-Schonlein purpura. Autoimmun Rev. 2008;7:179–184
  7. Lau KK, Wyatt RJ, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schonlein purpura. Pediatr Nephrol. 2007;22:2067–2072
  8. Brogan PA. What's new in the aetiopathogenesis of vasculitis?. Pediatr Nephrol. 2007;22:1083–1094
  9. Peru H, Soylemezoglu O, Bakkaloglu SA, et al. Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol. 2008;
  10. Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Schonlein purpura: a review of 261 patients. Acta Paediatr. 2004;93:1427–1431
  11. Ebert EC. Gastrointestinal Manifestations of Henoch-Schonlein Purpura. Dig Dis Sci. 2008;
  12. Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Schonlein purpura: a 10-year clinical study. Pediatr Nephrol. 2005;20:1269–1272
  13. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90:916–920
  14. Hamdan JM, Barqawi MA. Henoch-Schonlein purpura in children. Influence of age on the incidence of nephritis and arthritis. Saudi Med J. 2008;29:549–552
  15. de Almeida JL, Campos LM, Paim LB, et al. Renal involvement in Henoch-Schonlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr (Rio J). 2007;83:259–266
  16. Roberts PF, Waller TA, Brinker TM, et al. Henoch-Schonlein purpura: a review article. South Med J. 2007;100:821–824
  17. Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics. 2007;120:1079–1087
  18. Huber AM, King J, McLaine P, et al. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein Purpura. [ISRCTN85109383] BMC Med. 2004;2:7
  19. Ronkainen J, Koskimies O, la-Houhala M, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149:241–247
  20. Dillon MJ. Henoch-Schonlein purpura: recent advances. Clin Exp Rheumatol. 2007;25:S66–S68
  21. Zaffanello M, Brugnara M, Franchini M. Therapy for children with henoch-schonlein purpura nephritis: a systematic review. Scientific WorldJournal. 2007;7:20–30
  22. Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166:145–151
  23. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet. 2002;360:666–670
  24. Rees L, Webb NJA, Brogan PA. Henoch Schonlein Purpura. Oxford specialist handbook in paediatrics. Paediatric nephrology. 1st edn. Oxford Press; 2007;p. 310–313
  25. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114:1708–1733
  26. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL. Kawasaki disease: an overview. Curr Opin Infect Dis. 2008;21:263–270
  27. Park YW, Han JW, Park IS, et al. Kawasaki disease in Korea, 2003–2005. Pediatr Infect Dis J. 2007;26:821–823
  28. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004;16:508–514
  29. Burns JC. The riddle of Kawasaki disease. N Engl J Med. 2007;356:659–661
  30. Amano S, Hazama F, Kubagawa H, et al. General pathology of Kawasaki disease. On the morphological alterations corresponding to the clinical manifestations. Acta Pathol Jpn. 1980;30:681–694
  31. Newburger JW, Taubert KA, Shulman ST, et al. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4–7, 2001, Hakone, Japan. Pediatr Res. 2003;53:153–157
  32. Bronstein DE, Dille AN, Austin JP, et al. Relationship of climate, ethnicity and socioeconomic status to Kawasaki disease in San Diego County, 1994 through 1998. Pediatr Infect Dis J. 2000;19:1087–1091
  33. Rowley AH, Baker SC, Shulman ST, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis. 2005;192:1757–1766
  34. Chang LY, Chiang BL, Kao CL, et al. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis. 2006;193:283–286
  35. Matsubara K, Fukaya T, Miwa K, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol. 2006;143:427–434
  36. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40:35–42
  37. Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533–544
  38. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002;86:286–290
  39. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995;96:1057–1061
  40. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888–893
  41. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med. 2000;154:694–699
  42. Udi N, Yehuda S. Intravenous immunoglobulin - Indications and mechanisms in cardiovascular diseases. Autoimmun Rev. 2008;7:445–452
  43. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336–341
  44. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663–675
  45. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662–667
  46. Newburger JW, Fulton DR. Kawasaki Disease. Curr Treat Options Cardiovasc Med. 2007;9:148–158
  47. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145:517–522
  48. Rogalski C, Sticherling M. Panarteritis cutanea benigna–an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. Int J Dermatol. 2007;46:817–821
  49. Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infections. Clin Exp Rheumatol. 2006;24:S71–S81
  50. Cordier JF. Pulmonary manifestations of the vasculitides. Rev Prat. 2008;58:492–498
  51. David J, Ansell BM, Woo P. Polyarteritis nodosa associated with streptococcus. Arch Dis Child. 1993;69:685–688
  52. Trepo CG, Zucherman AJ, Bird RC, Prince AM. The role of circulating hepatitis B antigen/antibody immune complexes in the pathogenesis of vascular and hepatic manifestations in polyarteritis nodosa. J Clin Pathol. 1974;27:863–868
  53. Bakkaloglu A, Ozen S, Baskin E, et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa. Arch Dis Child. 2001;85:427–430
  54. Brogan PA, Shah V, Bagga A, et al. T cell Vbeta repertoires in childhood vasculitides. Clin Exp Immunol. 2003;131:517–527
  55. Ozen S, Ben-Chetrit E, Bakkaloglu A, et al. Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF?. Semin Arthritis Rheum. 2001;30:281–287
  56. Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep. 2004;6:203–211
  57. Brogan PA, Davies R, Gordon I, Dillon MJ. Renal angiography in children with polyarteritis nodosa. Pediatr Nephrol. 2002;17:277–283
  58. Dillon MJ. Vasculitis treatment - new therapeutic approaches. Eur J Pediatr. 2006;165:351–357
  59. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44
  60. de Kort SW, van Rossum MA, ten CR. Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol. 2006;25:769–771
  61. Sonomoto K, Miyamura T, Watanabe H, et al. A case of polyarteritis nodosa successfully treated by rituximab, Nihon Rinsho Meneki Gakkai Kaishi. 2008;31:119–123
  62. Melo M, Pilkington C, Hasson N, et al. Biologics in vasculitis of the young. Abstract. Young Investigators Meeting, 2006.
  63. Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol. 2006;142:1481–1482
  64. Brogan PA, Shah V, Dillon MJ. Polyarteritis nodosa in childhood. Abstract. 10th International Vasculitis and ANCA workshop. Cleveland, 2002.
  65. Cheung YF, Brogan PA, Pilla CB, et al. Arterial distensibility in children and teenagers: normal evolution and the effect of childhood vasculitis. Arch Dis Child. 2002;87:348–351
  66. Zwerina J, Eger G, Englbrecht M, et al. Churg-Strauss Syndrome in Childhood: A Systematic Literature Review and Clinical Comparison with Adult Patients. Semin Arthritis Rheum. 2008;
  67. Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol. 2002;17:754–761
  68. Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 2007;57:837–844
  69. Peco-Antic A, Bonaci-Nikolic B, Basta-Jovanovic G, et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr Nephrol. 2006;21:46–53
  70. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–275
  71. Park MC, Lee SW, Park YB, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005;34:284–292
  72. Cakar N, Yalcinkaya F, Duzova A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35:913–919
  73. Desai MY, Stone JH, Foo TK, et al. Delayed contrast-enhanced MRI of the aortic wall in Takayasu's arteritis: initial experience. AJR Am J Roentgenol. 2005;184:1427–1431
  74. Webb M, Al-Nahhas A. Molecular imaging of Takayasu's arteritis and other large-vessel vasculitis with 18F-FDG PET. Nucl Med Commun. 2006;27:547–549
  75. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;17:16–24
  76. Ozen S, Duzova A, Bakkaloglu A, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150:72–76
  77. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296–2304
  78. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol. 2004;31:102–106

PII: S1521-6942(09)00022-9

doi: 10.1016/j.berh.2009.02.001

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 309-323 , June 2009

Article Tools